Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Inclusion Criteria : * Aged 42 to 84 days (6 to 12 weeks) or 24 to 36 weeks on the day of inclusion. * Born at full term of pregnancy (≥ 36 weeks) with a birth weight ≥ 2.5 kg. * Considered to be in good health on the basis of reported medical history and history-directed physical examination. * Available for the duration of the study. * Parent/guardian willing and able to provide informed consent. * Parent/guardian able to attend all scheduled visits and comply with all trial procedures. * Willingness to permit venipuncture or heel stick for purposes of collecting a blood sample. Exclusion Criteria : * Reported allergy to egg proteins, chicken proteins or any other constituent of the vaccine. * Previous history of influenza vaccination or documented history of influenza infection. * Receipt of any vaccine in the 7 days prior to enrollment. * An acute illness with fever (rectal temperature ≥ 38.0 °C \[or ≥ 100.4 °F\]) in the 72 hours preceding enrollment in the trial (defer enrollment). * Known bleeding disorder. * Participation in any other clinical trial within 30 days prior to enrollment, or planned participation in another clinical trial prior to termination of the subject's participation in this study. * Known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth. * Personal or immediate family history of congenital immune deficiency. * Developmental delay, neurologic disorder, or seizure disorder. * Chronic medical, congenital or developmental disorder that could interfere with trial conduct or completion. * Known HIV-positive or HBsAg-positive mother. * Known HIV, hepatitis B (HBsAg), or hepatitis C infection. * Blood or blood-derived products received in the past 2 months. * Prior history of Guillain-Barré syndrome. * Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.